Literature DB >> 8977709

Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo.

R L Barnhill1, M Xiao, D Graves, H N Antoniades.   

Abstract

There has been considerable interest in the potential role of growth factors in the initiation and development of cutaneous malignant melanoma (CMM). Platelet-derived growth factor (PDGF) has been shown to be secreted by melanoma cell lines and by metastatic melanoma in vivo. PDGF also has been reported to stimulate the development of tumour stroma and new blood vessels. We studied the expression of PDGF and its receptors by both immunohistochemistry (IHC) and in situ hybridization (ISH) in primary and metastatic melanoma and in normal skin specimens. Cryostat sections were incubated with 35S-labelled riboprobes and antibodies for PDGF-AA, PDGF-alpha receptor, PDGF-BB and PDGF-beta receptor. Both primary and metastatic melanoma exhibited significant expression of PDGF-AA, PDGF-BB and PDGF-alpha receptor by both IHC and ISH, compared with only background expression in normal skin. We did not observe expression of PDGF-beta receptor in melanoma. Our results suggest that PDGF may function as an autocrine growth factor, as well as an angiogenesis factor, in CMM tumour development. This expression of the PDGF-alpha receptor rather than the beta receptor may be unique among solid tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977709     DOI: 10.1046/j.1365-2133.1996.d01-1092.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

2.  Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Authors:  Ju-Won Roh; Jie Huang; Wei Hu; XiaoYun Yang; Nicholas B Jennings; Vasudha Sehgal; Bo Hwa Sohn; Hee Dong Han; Sun Joo Lee; Duangmani Thanapprapasr; Justin Bottsford-Miller; Behrouz Zand; Heather J Dalton; Rebecca A Previs; Ashley N Davis; Koji Matsuo; Ju-Seog Lee; Prahlad Ram; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 3.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

4.  Triplex targeting of human PDGF-B (c-sis, proto-oncogene) promoter specifically inhibits factors binding and PDGF-B transcription.

Authors:  J Liu; R Xu; Y Jin; D Wang
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

5.  Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases.

Authors:  M Udart; J Utikal; G M Krähn; R U Peter
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

6.  A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum.

Authors:  Caterina Longo; Guido Gambara; Virginia Espina; Alessandra Luchini; Barney Bishop; Alexis S Patanarut; Emanuel F Petricoin; Francesca Beretti; Barbara Ferrari; Enrico Garaci; Anto De Pol; Giovanni Pellacani; Lance A Liotta
Journal:  Exp Dermatol       Date:  2011-01       Impact factor: 3.960

7.  Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.

Authors:  Keith T Flaherty; Betty K Hamilton; Mark A Rosen; Ravi K Amaravadi; Lynn M Schuchter; Maryann Gallagher; Helen Chen; Chandra Sehgal; Peter J O'Dwyer
Journal:  Oncologist       Date:  2015-06-17

8.  Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.

Authors:  A S Mansfield; W K Nevala; R S Dronca; A A Leontovich; L Shuster; S N Markovic
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

9.  Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Authors:  Cindy S Hwang; Victor G Prieto; Abdul H Diwan; Gregory Lizee; Julie A Ellerhorst; Suhendan Ekmekcioglu; Ping Liu; Omar Eton; Sandra A Kinney; Elizabeth A Grimm; Patrick Hwu; Kevin B Kim
Journal:  Melanoma Res       Date:  2008-08       Impact factor: 3.599

10.  Phase II trial of imatinib mesylate in patients with metastatic melanoma.

Authors:  K B Kim; O Eton; D W Davis; M L Frazier; D J McConkey; A H Diwan; N E Papadopoulos; A Y Bedikian; L H Camacho; M I Ross; J N Cormier; J E Gershenwald; J E Lee; P F Mansfield; L A Billings; C S Ng; C Charnsangavej; M Bar-Eli; M M Johnson; A J Murgo; V G Prieto
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.